Cantor Fitzgerald Reiterate Hold Following Ligand Pharma's (LGND) Strong Q1
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ligand Reports First Quarter 2015 Financial Results
May 11, 2015 8:31 AM EDTConference Call Begins at 9:00 a.m. Eastern Time Today
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2015, and provided an operating forecast and program updates.
Financial highlights for the first quarter of 2015 include:
Total revenues were $14.6 million and royalty revenues were $10.3 million, an increase of 31% compared with the first quarter of 2014 Adjusted EPS was $0.33 and GAAP EPS was $0.04 The company generated operating cash of $7.6 million, a significant... MoreLigand Acquires Rights to More Than 15 Fully-Funded Development Programs from Selexis SA
May 11, 2015 8:15 AM EDTLigands Portfolio of Fully-Funded Partnered Assets Now Exceeds 120
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has acquired a portfolio of potential future milestone and royalty payments for more than 15 biologic development programs from Selexis SA for $4 million in cash. Highlights of the transaction include the following:
The basis for the development programs and economic rights is a proprietary technology for manufacturing stable and high performing mammalian cell lines for biologic therapeutics The acquired assets include a mix of novel biologics and biosimilars... More